Perhaps PD-1 inhibitors just aren’t for ovarian cancer after all. | Merck's and GSK's similar overall survival setbacks ...

First approved in 2021, Jemperli has now become a cornerstone of GSK’s cancer business, earning more than $160 million in the ...

GSK said on Friday that adding its cancer drug Jemperli to both standard-of-care chemotherapy and Zejula as a maintenance ...

UK pharma major GSK today released mixed headline results from the FIRST-ENGOT-OV44 Phase III trial evaluating Zejula ...

GSK plc（伦敦证券交易所/纽约证券交易所代码：GSK），一家市值673.5亿美元、目前交易价格接近52周低点的知名制药公司，今天公布了其FIRST三期临床试验的积极结果。该试验评估了Zejula（尼拉帕利）和Jemperli（dostarlimab）在治疗晚期卵巢癌方面的效果。

A combination of presurgical Zejula and Jemperli showed promising treatment responses in certain patients with ER-positive, ...

GSK said on Friday the addition of its cancer drug Jemperli to both standard of care chemotherapy and Zejula maintenance ...

GSK’s FIRST-ENGOT-OV44 phase III clinical trial of Zejula and Jemperl in first line advanced ovarian cancer meets primary endpoint: London Saturday, December 21, 2024, 09:00 Hrs ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

This week's health news featured pivotal developments in pharmaceutical trials. GSK's cancer drug combo showed promising ...